SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Traboulsee, A
Right arrow Articles by Miller, D H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traboulsee, A
Right arrow Articles by Miller, D H
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities

A Traboulsee

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK, MS/MRI Research Group, University of British Columbia, Vancouver, BC, Canada, trabouls{at}interchange.ubc.ca

J Dehmeshki

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

Kevin R Peters

Department of Psychology, University of British Columbia, Vancouver, BC, Canada

C M Griffin

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

P A Brex

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

N Silver

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

O Ciccarrelli

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

D T Chard

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

G J Barker

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

A J Thompson

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

D H Miller

NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK

Background: Magnetization transfer ratio (MTR) histogram analysis provides a global measure of disease burden in multiple sclerosis (MS). MTR abnormalities in normal appearing brain tissue (NABT) provide quantitative information on the extent of tissue damage undetected by conventional T2-weighted (T2W) magnetic resonance imaging (MRI). A ims: 1) To compare the MTR histograms from NABT across a broad spectrum of relapse onset MS patients, including relapsing-remitting (RR) MS (including newly diagnosed and benign subgroups) and secondary progressive (SP) MS. 2) To determine the relationship between clinical disability and NA BT MTR histograms. Methods: 2D spin echo magnetization transfer imaging was performed on 70 RRMS and 25 SPMS patients and compared with 63 controls. MTR histograms were acquired for NA BT after extracting lesions and cerebrospinal fluid (C SF). T2W images were used to measure the brain parenchymal fraction (BPF) and T2 lesion load. Results: MS patients had a disease duration ranging from 0.5 to 37 years and an Expanded Disability Status Scale (EDSS) score ranging from 0 to 8.5. There was a significant decrease in NA BT mean MTR (± standard deviation) compared with controls (33.07 pu± 1.06 versus 34.26 pu± 0.47; P < 0.001) with an effect size of 2.56. The reductio n in NA BT mean MTR varied among patient groups from 4.9% for SPMS, 3% for all RRMS, 2.7% for early RRMS and 2.5% for benign MS, compared with controls. NA BT mean MTR correlated significantly with T2 lesion load (r = -0.82) and BPF (r =0.58). EDSS score correlated with NA BT mean MTR (r = -0.43), BPF (r = -0.33) and with T2 lesion load (r =0.59). Multivariate analysis using NA BT MTR peak height, T2 lesion load and BPF combined only accounted for 38% of the variance in the EDSS (r =0.62; P <0.001). Disease duration accounted for an additional 14% of variance in the EDSS (r =0.72; P <0.001). Conclusions: There is evidence of diffuse abnormalities in NA BT in addition to global brain atrophy in relapse onset MS patients, including those with recently diagnosed RRMS and benign MS. The abnormalities are greatest in patients with the more disabling SPMS. A trophy, NA BT and lesion abnormalities are all partly correlated; the processes marked by these MR measures all contribute to disability in MS, providing complementary information relevant to the complex pathological processes that occur in MS.

Key Words: brain atrophy • histogram • magnetic resonance imaging • MRI • magnetization transfer imaging • magnetization transfer ratio • MTR • multiple sclerosis • normal appearing brain tissue

Multiple Sclerosis, Vol. 9, No. 6, 566-573 (2003)
DOI: 10.1191/1352458503ms958oa


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Mult SclerHome page
A Ceccarelli, M Filippi, M Neema, A Arora, P Valsasina, M. Rocca, B. Healy, and R Bakshi
T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis
Multiple Sclerosis, June 1, 2009; 15(6): 678 - 686.
[Abstract] [PDF]


Home page
NeurologyHome page
M. Rovaris, F. Barkhof, M. Calabrese, N. De Stefano, F. Fazekas, D. H. Miller, X. Montalban, C. Polman, M. A. Rocca, A. J. Thompson, et al.
MRI features of benign multiple sclerosis: Toward a new definition of this disease phenotype
Neurology, May 12, 2009; 72(19): 1693 - 1701.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. P. Amato, E. Portaccio, M. L. Stromillo, B. Goretti, V. Zipoli, G. Siracusa, M. Battaglini, A. Giorgio, M. L. Bartolozzi, L. Guidi, et al.
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis
Neurology, August 26, 2008; 71(9): 632 - 638.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
S. Strasser-Fuchs, C. Enzinger, S. Ropele, M. Wallner, and F. Fazekas
Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox?
Multiple Sclerosis, March 1, 2008; 14(2): 205 - 211.
[Abstract] [PDF]


Home page
NeurologyHome page
L. Kappos, A. Traboulsee, C. Constantinescu, J. -P. Eralinna, F. Forrestal, P. Jongen, J. Pollard, M. Sandberg-Wollheim, C. Sindic, B. Stubinski, et al.
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Neurology, September 26, 2006; 67(6): 944 - 953.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
N. De Stefano, M. Battaglini, M. L. Stromillo, V. Zipoli, M. L. Bartolozzi, L. Guidi, G. Siracusa, E. Portaccio, A. Giorgio, S. Sorbi, et al.
Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis
Brain, August 1, 2006; 129(8): 2008 - 2016.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
H. Vrenken, S.A.R.B. Rombouts, P.J.W. Pouwels, and F. Barkhof
Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter.
AJNR Am. J. Neuroradiol., April 1, 2006; 27(4): 868 - 874.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. A. Rudick, W. H. Stuart, P. A. Calabresi, C. Confavreux, S. L. Galetta, E.-W. Radue, F. D. Lublin, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, et al.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
N. Engl. J. Med., March 2, 2006; 354(9): 911 - 923.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. Imitola, T. Chitnis, and S. J. Khoury
Insights Into the Molecular Pathogenesis of Progression in Multiple Sclerosis: Potential Implications for Future Therapies
Arch Neurol, January 1, 2006; 63(1): 25 - 33.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
K. T. M. Fernando, D. J. Tozer, K. A. Miszkiel, R. M. Gordon, J. K. Swanton, C. M. Dalton, G. J. Barker, G. T. Plant, A. J. Thompson, and D. H. Miller
Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis
Brain, December 1, 2005; 128(12): 2911 - 2925.
[Abstract] [Full Text] [PDF]



Advertisement